Psychedelic Science Newsletter
Issue #31April 6, 20267 studies

31% of people with distressing psychedelic experiences met criteria for PTSD

This week's psychedelic research reveals both promise and caution—from NHS implementation models to unexpected trauma outcomes.

🧠 Difficult psychedelic trips can trigger lasting PTSD symptoms

  • 31.3% of 243 people who had distressing psychedelic experiences met diagnostic criteria for PTSD based on self-report measures

  • PTSD symptoms were strongly linked to how people responded during the acute experience—avoidance-related reactions predicted worse outcomes, while acceptance-related responses were protective

  • Most participants sought help afterward, with psychotherapy rated as the most helpful intervention, though online resources and friends/family were more commonly accessed

Why it matters: As psychedelic use expands beyond clinical settings, this provides the first systematic evidence that challenging trips can sometimes lead to trauma-like symptoms lasting well beyond the acute phase.

🔗 Psychological medicine Journal Article 🗓️ Apr 1

Key Findings

🏥 UK researchers outline how psilocybin could work in the NHS

  • Researchers propose a model for delivering psilocybin treatment through publicly funded health services like the NHS

  • The approach combines oral psilocybin (which has effects lasting 6-8 hours) with psychological support, though the exact role of this support remains debated

  • The model aims to ensure equitable access to these treatments for all patients, not just those who can afford private care

💡 This planning could help make psychedelic therapy accessible to broader populations once treatments receive regulatory approval.

🔬 Psilocybin dampens bad memories in mouse brains

  • In mice, psilocybin selectively reduced brain responses to aversive stimuli and sounds previously linked to negative experiences

  • The drug didn't affect responses to rewards or newly formed negative associations—only well-established aversive memories

  • Brain imaging showed psilocybin increased coordination between neurons initially, then later reduced it specifically among cells encoding negative associations

💡 This suggests psilocybin may preferentially target entrenched negative memories rather than affecting all emotional processing.

✨ Mystical experiences linked to mood improvements across conditions

  • Across 13 clinical trials with 410 participants, 69% of studies found positive relationships between mystical-type experiences and reduced anxiety/depression

  • The link was stronger in people with life-threatening diseases (80% of studies) compared to those with depression alone (63%)

  • The relationship appeared to depend on factors like timing of symptom assessments and therapeutic context

💡 Mystical experiences may be a key mechanism for psychedelic therapy benefits, but the relationship isn't universal.
Top 20% journal 🔗 Therapeutic advances in psychopharmacology Review 🗓️ Apr 1

🌱 Scientists engineer plants to produce multiple psychedelics

  • Researchers reconstructed complete biosynthetic pathways for five natural psychedelics in plants: psilocin, psilocybin, DMT, bufotenin, and 5-methoxy-DMT

  • They combined genetic functions from plants, fungi, and animals to create more efficient production systems

  • The approach also enabled creation of halogenated analogs that don't occur naturally but may have therapeutic potential

💡 This could provide a scalable platform for producing psychedelic compounds for research and eventual clinical use.
🥈 Top 2% journal 🔗 Science advances Journal Article 🗓️ Apr 1

🩺 Australian clinicians see psychedelics as tools to "unlock stuckness"

  • Focus groups with 18 clinicians and service leaders revealed three different views of psilocybin therapy: last resort treatment, tool for overcoming therapeutic plateaus, or catalyst for rapid progress

  • Clinicians emphasized the need for careful integration, robust support, and aftercare alongside concerns about access and eligibility

  • Both groups understood psilocybin therapy as complex, dependent on medication, therapist skill, client readiness, and care context working together

💡 Implementation success may depend on how well clinical teams can adapt the approach to local contexts and patient needs.
🥉 Top 5% journal 🔗 Addiction (Abingdon, England) Journal Article 🗓️ Mar 30

⚠️ Computer models predict toxicity risks for LSD-like compounds

  • Researchers used multiple computational platforms to predict toxicity for five LSD derivatives commonly found as new psychoactive substances

  • Predicted lethal doses ranged from 49-85 mg/kg in rats, with 1V-LSD and 1cP-LSD showing highest pulmonary risks (92% and 81% respectively)

  • ALD-52 and 1cP-LSD showed consistent alerts for potential genetic damage across prediction models

💡 These predictions could help prioritize which LSD analogs need urgent safety testing as they appear in illegal drug markets.
🔗 Archives of toxicology Journal Article 🗓️ Mar 31

Implications

This week's research highlights the complex reality of psychedelic medicine—while these compounds show therapeutic promise and researchers work toward clinical implementation, they also carry real risks that vary significantly between substances and contexts. The challenge ahead is developing frameworks that maximize benefits while minimizing harm as use expands.

Studies in this issue

Primary sources used for this newsletter.

  1. PTSD symptoms after using psychedelics in a real-world survey
    main storyPsychological medicine2026-04-01PMID 41919323
  2. Using psilocybin in NHS services: a practical model for real-world treatment
    key findingThe British journal of psychiatry : the journal of mental science2026-03-30PMID 41906234
  3. Psilocybin reduces brain responses to unpleasant sounds in the mouse hearing system
    key findingbioRxiv : the preprint server for biology2026-04-03PMID 41929185
  4. Mystical-like experiences and mood changes in psychedelic therapy for life-threatening illness versus depression
    key findingTherapeutic advances in psychopharmacology2026-04-01PMID 41918771